Progenics Pharmaceuticals IncPGNX:NSQ

Add to portfolio
Set alert
Interactive chart
Historical prices
Data definitions
4.31
0.18 / 4.36%
1.43m
45.44%
1.12
Close in USDToday's changeShares traded1 year changeBeta
As of May 17 2013 21:00 BST.Data delayed by at least 15 minutes.

Interactive chart

Summary

On Friday, Progenics Pharmaceuticals Inc (PGNX:NSQ) closed at 4.31, 205.67% above the 52 week low of 1.41 set on Nov 13, 2012.

52-week range
Today
1.41
Nov 13 2012
11.00
Jul 27 2012
Markit short selling activity
Low
Medium
High
What is this
Open4.15
Day high4.44
Day low4.02
Bid4.35
Offer4.36
Previous close4.13
Average volume380.46k
Shares outstanding51.04m
Free float49.12m
P/E (TTM)--
Market cap219.98m USD
EPS (TTM)-0.8843 USD

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Progenics Pharmaceuticals Inc-3.15%-5.90%+131.72%-45.44%-65.38%
S&P 500 INDEX+2.07%+7.44%+22.62%+27.79%+16.99%
USA/HEALTH CARE+1.67%+4.66%+21.05%+26.74%--
USA/BIOTECHNOLOGY+1.65%+8.57%+31.99%+42.33%--
As of May 17 2013 21:00 BST.Data delayed by at least 15 minutes.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.